Genotypic Characterization of Mycobacterium Tuberculosis Strains Resistant to Rifampicin, Isoniazid and Second-Line Antibiotics in Chad

Journal Title: Journal of Clinical Immunology & Microbiology - Year 2024, Vol 5, Issue 1

Abstract

Monitoring drug resistance and identifying the genetic basis of resistance to first- and second-line anti-tuberculosis (anti-TB) drugs provides important information to optimize patient care. The present study was an observational, cross-sectional and analytical study aimed at determining the prevalence of resistance genes to rifampicin, isoniazid and resistant and multi-resistant genes with mutations associated with second-line anti-tuberculosis drugs (Levofloxacin Amikacin, Kanamycin and Capreomycin) among strains of Mycobacterium tuberculosis in nine hospitals in four provinces of Chad with three new molecular techniques. The TB-LAMP molecular technique made it possible to detect 264 (25.14%) strains of Mycobacterium tuberculosis complex among 1050 people referred for tuberculosis research, including 37 cases in relapse and 237 new cases under treatment or not without clinical improvement. The average age of the patients was 34.15 years with the extremes ranging from 12 to 77 years. The sex ratio was 3.33 in favor of men. The GeneXpert made it possible to confirm the 264 positive cases of Mycobacterium tuberculosis (MTB+) of which 76% of men and 24% of women had the MTB+ profile sensitive to rifampicin, and 80% of men and 20% of women harbored the Mycobacterium complex. rifampicin-resistant tuberculosis. The determination of resistance genes including 13% (rpoB) to rifampicin, 4% (inhA) to isoniazid and 8% (rpoB/KatG and/or KatG/inhA) multi-resistant (MDR) genes was carried out using the Line Probe Assay technique. This technique also made it possible to determine resistance genes with associated mutations including 13.6% (gyrA and gyrB), 7.6% (eis), 6.1% (rrs and eis) and 10.6% being mutations affecting the different alleles on the chromosomes of the Mycobacterium tuberculosis complex. This study highlighted the emergence of resistance to rifampicin and isoniazid as well as resistance with mutations associated with second-line anti-tuberculosis drugs. It raises the need to implement an effective surveillance system to detect the resistance of Mycobacterium tuberculosis to anti-tuberculosis drugs in Chad and even in Central Africa.

Authors and Affiliations

Djimenan Boilengar3, Nadlaou Bessimbaye1,3*, Rimtebaye Kimassoum2

Keywords

Related Articles

Humble Opinions on the Five Very Important Papers

I have the honor to address the 126 critical problems raised by Shanghai Jiao tong University and Chief Editor of Science in celebrating the university’s 126 anniversary [1-5]. My humble opinions and comments are as fo...

Antibiotic Profile of Biofilm Producing Coagulase Negative Staphylococci Isolated from Various Clinical Specimens

Introduction: CoNS which are normal commensal of skin and mucous membranes of human, when presented with an opportunity, are known to cause infections. The most common species among the group are the S. epidermidis. Prod...

Immuno-Multi-Therapy and Prophylaxis Efficacy against COVID-19

In the context of the current COVID-19 pandemic, strategies for finding effective therapies advocate the so-called "therapeutic repositioning" approach, i.e., the use of existing molecules on the pharmaceutical market,...

How Stress Causes Cancer and Alzheimer Disease: The Extracellular Space and the Role of the Lymph System

The article claims based on Russian studies that cancer is caused by crystallin formations in the spaces between the cells, which disconnect the cells. In a cut wound, the disconnected cells start to multiply fast to hea...

Download PDF file
  • EP ID EP733784
  • DOI http://dx.doi.org/10.46889/JCIM.2024.5108
  • Views 31
  • Downloads 0

How To Cite

Djimenan Boilengar3, Nadlaou Bessimbaye1, 3*, Rimtebaye Kimassoum2 (2024). Genotypic Characterization of Mycobacterium Tuberculosis Strains Resistant to Rifampicin, Isoniazid and Second-Line Antibiotics in Chad. Journal of Clinical Immunology & Microbiology, 5(1), -. https://europub.co.uk/articles/-A-733784